KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Accured Expenses (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Change in Accured Expenses for 15 consecutive years, with $16.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 4030.07% to $16.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$7.6 million, a 152.72% decrease, with the full-year FY2025 number at -$7.6 million, down 152.72% from a year prior.
  • Change in Accured Expenses was $16.5 million for Q4 2025 at Supernus Pharmaceuticals, up from -$21.5 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $57.4 million in Q2 2021 to a low of -$63.1 million in Q3 2021.
  • A 5-year average of $1.6 million and a median of -$2.1 million in 2023 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: plummeted 785.19% in 2021, then skyrocketed 4030.07% in 2025.
  • Supernus Pharmaceuticals' Change in Accured Expenses stood at $20.2 million in 2021, then skyrocketed by 56.22% to $31.6 million in 2022, then crashed by 125.95% to -$8.2 million in 2023, then skyrocketed by 94.89% to -$419000.0 in 2024, then surged by 4030.07% to $16.5 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Change in Accured Expenses are $16.5 million (Q4 2025), -$21.5 million (Q3 2025), and -$4.0 million (Q2 2025).